Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13,

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. IMNN
8. NAVN
9. DFTX
10. META

Go back to Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13,
(NASDAQ: ALLO) Delayed: 2.09 -0.01 (0.48%)
Previous Close $2.10    52 Week High $ 
Open $2.09    52 Week Low $ 
Day High $2.09    P/E N/A 
Day Low $2.09    EPS $ 
Volume 17,423